Tower Research Capital (TRC)’s Phathom Pharmaceuticals PHAT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $54.8K | Buy |
5,710
+2,102
| +58% | +$20.2K | ﹤0.01% | 2898 |
|
|
2025
Q1 | $22.6K | Sell |
3,608
-806
| -18% | -$5.05K | ﹤0.01% | 2844 |
|
|
2024
Q4 | $35.8K | Buy |
4,414
+27
| +0.6% | +$219 | ﹤0.01% | 2779 |
|
|
2024
Q3 | $79.3K | Sell |
4,387
-1,426
| -25% | -$25.8K | ﹤0.01% | 2418 |
|
|
2024
Q2 | $59.9K | Buy |
5,813
+5,233
| +902% | +$53.9K | ﹤0.01% | 2956 |
|
|
2024
Q1 | $6.16K | Sell |
580
-9,281
| -94% | -$98.6K | ﹤0.01% | 4422 |
|
|
2023
Q4 | $90K | Buy |
9,861
+550
| +6% | +$5.02K | ﹤0.01% | 2726 |
|
|
2023
Q3 | $96.6K | Buy |
9,311
+8,834
| +1,852% | +$91.6K | ﹤0.01% | 2007 |
|
|
2023
Q2 | $6.83K | Sell |
477
-1,228
| -72% | -$17.6K | ﹤0.01% | 4631 |
|
|
2023
Q1 | $12K | Buy |
1,705
+1,219
| +251% | +$8.58K | ﹤0.01% | 4112 |
|
|
2022
Q4 | $5K | Sell |
486
-3,965
| -89% | -$40.8K | ﹤0.01% | 4896 |
|
|
2022
Q3 | $49K | Sell |
4,451
-929
| -17% | -$10.2K | ﹤0.01% | 3174 |
|
|
2022
Q2 | $45K | Buy |
5,380
+1,684
| +46% | +$14.1K | ﹤0.01% | 2991 |
|
|
2022
Q1 | $51K | Buy |
3,696
+3,280
| +788% | +$45.3K | ﹤0.01% | 2715 |
|
|
2021
Q4 | $8K | Sell |
416
-190
| -31% | -$3.65K | ﹤0.01% | 4816 |
|
|
2021
Q3 | $19K | Sell |
606
-3,227
| -84% | -$101K | ﹤0.01% | 3769 |
|
|
2021
Q2 | $130K | Buy |
3,833
+2,517
| +191% | +$85.4K | ﹤0.01% | 2214 |
|
|
2021
Q1 | $49K | Sell |
1,316
-841
| -39% | -$31.3K | ﹤0.01% | 3150 |
|
|
2020
Q4 | $72K | Sell |
2,157
-9,055
| -81% | -$302K | ﹤0.01% | 2695 |
|
|
2020
Q3 | $411K | Buy |
11,212
+9,058
| +421% | +$332K | ﹤0.01% | 1901 |
|
|
2020
Q2 | $71K | Buy |
+2,154
| New | +$71K | ﹤0.01% | 2763 |
|